Desmethylflunitrazepam: Difference between revisions

Latest revision as of 16:26, 16 February 2025

Desmethylflunitrazepam[edit]

Chemical structure of Desmethylflunitrazepam

Desmethylflunitrazepam is a benzodiazepine derivative and an active metabolite of flunitrazepam, commonly known by the brand name Rohypnol. It is known for its sedative, anxiolytic, muscle relaxant, and anticonvulsant properties. Desmethylflunitrazepam is primarily used in the context of its parent compound, flunitrazepam, which is a potent hypnotic agent.

Pharmacology[edit]

Desmethylflunitrazepam acts on the central nervous system by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor. This action results in increased neuronal inhibition, leading to the sedative and anxiolytic effects characteristic of benzodiazepines.

Metabolism[edit]

Desmethylflunitrazepam is formed in the body as a result of the metabolism of flunitrazepam. The primary metabolic pathway involves the N-demethylation of flunitrazepam, which is catalyzed by the cytochrome P450 enzyme system in the liver. This metabolite retains pharmacological activity and contributes to the overall effects of flunitrazepam.

Clinical Use[edit]

While desmethylflunitrazepam itself is not marketed as a separate pharmaceutical product, its presence is significant in the context of flunitrazepam use. Flunitrazepam is prescribed for the short-term treatment of severe insomnia and is sometimes used as a premedication in surgical procedures due to its strong sedative effects.

Legal Status[edit]

Due to its association with flunitrazepam, desmethylflunitrazepam is subject to similar legal restrictions. Flunitrazepam is classified as a Schedule IV controlled substance under the Controlled Substances Act in the United States and is similarly regulated in many other countries due to concerns about its potential for abuse and its use in drug-facilitated crimes.

Related Pages[edit]

Benzodiazipines[edit]

Anticonvulsants Drugs[edit]

Anticonvulsants, and Benzodiazepines]

@@ Line 1: / Line 1: @@
-'''Desmethylflunitrazepam''' is a [[pharmacology|pharmacological]] substance that is classified as a [[benzodiazepine]]. It is a metabolite of the well-known drug [[flunitrazepam]], which is commonly known as Rohypnol.
+== Desmethylflunitrazepam ==
-==Chemistry==
+[[File:Desmethylflunitrazepam.svg|thumb|right|Chemical structure of Desmethylflunitrazepam]]
-Desmethylflunitrazepam, like all benzodiazepines, has a core structure of a [[benzene]] ring fused to a [[diazepine]] ring. The difference between desmethylflunitrazepam and flunitrazepam is the absence of a methyl group on the nitrogen atom in the diazepine ring. This small structural change results in a significant difference in the pharmacological activity of the two substances.
-==Pharmacology==
+'''Desmethylflunitrazepam''' is a [[benzodiazepine]] derivative and an active metabolite of [[flunitrazepam]], commonly known by the brand name [[Rohypnol]]. It is known for its sedative, anxiolytic, muscle relaxant, and anticonvulsant properties. Desmethylflunitrazepam is primarily used in the context of its parent compound, flunitrazepam, which is a potent hypnotic agent.
-Desmethylflunitrazepam acts as an [[agonist]] at the [[GABA_A receptor]], the same mechanism of action as other benzodiazepines. This results in an increase in the inhibitory effects of the neurotransmitter [[GABA]], leading to sedative and anxiolytic effects.
-==Medical Use==
+== Pharmacology ==
-While desmethylflunitrazepam itself is not typically used in medicine, its parent compound flunitrazepam is used in some countries as a treatment for severe [[insomnia]]. However, it is not commonly used due to its high potential for [[dependence]] and [[withdrawal]] symptoms.
-==Legal Status==
+Desmethylflunitrazepam acts on the [[central nervous system]] by enhancing the effect of the neurotransmitter [[gamma-aminobutyric acid]] (GABA) at the [[GABA_A receptor]]. This action results in increased neuronal inhibition, leading to the sedative and anxiolytic effects characteristic of benzodiazepines.
-Desmethylflunitrazepam is a controlled substance in many countries due to its potential for abuse and dependence. In the United States, it is classified as a Schedule IV controlled substance under the [[Controlled Substances Act]].
-==See Also==
+== Metabolism ==
+Desmethylflunitrazepam is formed in the body as a result of the [[metabolism]] of flunitrazepam. The primary metabolic pathway involves the [[N-demethylation]] of flunitrazepam, which is catalyzed by the [[cytochrome P450]] enzyme system in the [[liver]]. This metabolite retains pharmacological activity and contributes to the overall effects of flunitrazepam.
+== Clinical Use ==
+While desmethylflunitrazepam itself is not marketed as a separate pharmaceutical product, its presence is significant in the context of flunitrazepam use. Flunitrazepam is prescribed for the short-term treatment of severe [[insomnia]] and is sometimes used as a premedication in [[surgical procedures]] due to its strong sedative effects.
+== Legal Status ==
+Due to its association with flunitrazepam, desmethylflunitrazepam is subject to similar [[legal restrictions]]. Flunitrazepam is classified as a [[Schedule IV controlled substance]] under the [[Controlled Substances Act]] in the United States and is similarly regulated in many other countries due to concerns about its potential for abuse and its use in [[drug-facilitated crimes]].
+== Related Pages ==
+* [[Flunitrazepam]]
 * [[Benzodiazepine]]
-* [[Flunitrazepam]]
 * [[GABA_A receptor]]
+* [[Metabolism]]
+{{Benzodiazepines}}
-[[Category:Pharmacology]]
 [[Category:Benzodiazepines]]
-[[Category:Controlled substances]]
+[[Category:Sedatives]]
+[[Category:Anxiolytics]]
-{{medicine-stub}}